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The urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) catalyzes the initial step 
of the urea cycle; bi-allelic mutations typically present with hyperammonemia, vomiting, ataxia, 
lethargy progressing into coma, and death due to brain edema if ineffectively treated. The enzyme 
deficiency is particularly difficult to treat; early recognition is essential to minimize injury to the 
brain. Even under optimal conditions, therapeutic interventions are of limited scope and efficacy, 
with most patients developing long-term neurologic sequelae. One significant encumberment to 
gene therapeutic development is the size of the CPS1 cDNA which, at 4.5kb, nears the packaging 
capacity of adeno-associated virus (AAV). Herein we developed a split AAV (sAAV)-based 
approach, packaging the large transgene and its regulatory cassette into two separate vectors, 
thereby delivering therapeutic CPS1 by a dual vector system with testing in a murine model of the 
disorder. Cps1-deficient mice treated with sAAVs survive long-term with markedly improved 
ammonia levels, diminished dysregulation of circulating amino acids, and increased hepatic CPS1 
expression and activity. In response to acute ammonia challenging, sAAV-treated female mice 
rapidly incorporated nitrogen into urea. This study demonstrates the first proof-of-principle that 
sAAV-mediated therapy is a viable, potentially clinically translatable approach to CPS1 





 Carbamoyl phosphate synthetase 1 (CPS1; E.C. 6.3.4.16) catalyzes the ATP-dependent 
condensation of ammonia and bicarbonate into carbamoyl phosphate1, which subsequently 
proceeds through the urea cycle in hepatocytes or the arginine biosynthesis pathway in intestinal 
epithelium2. CPS1 resides in the mitochondria, where its function is dependent on the allosteric 
activator N-acetylglutamate (NAG). CPS1 deficiency (OMIM #237300) is a rare autosomal 
recessive disorder caused by mutations in the CPS1 gene leading to diminished or abolished CPS1 
protein function. The estimated incidence is 1 in 1.3 million in the United States and Europe3, 
though estimates vary widely4 and this is likely an underestimate due to the difficulty in making 
an accurate early diagnosis. 
Patients afflicted with CPS1 deficiency often present in the neonatal period with vomiting, 
lethargy, and coma due to elevated plasma ammonia. With acute life-threatening episodes of 
hyperammonemia, hemodialysis may be necessary. Timely and aggressive treatment is essential 
for reducing plasma ammonia to prevent mortality; however, these treatments are typically unable 
to prevent marked hyperammonemic episodes and cannot reverse neurological injury that has been 
acquired during these crises. Even in the best of circumstances, patients often remain severely 
nitrogen vulnerable. Current chronic treatment strategies rely primarily on dietary protein 
restriction and ammonia scavenger administration in combination with L-arginine and/or L-
citrulline supplementation5. 
 Recent advances in gene therapy have led to the concept of treating CPS1 deficiency using 
adeno-associated virus (AAV)-based technology; as a monogenic disorder that is a well-defined 
enzyme deficiency with no completely effective medical treatment except liver transplantation 
(which has accompanying inherent risks, both short- and long-term), it is an appropriate disorder 
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to target for therapeutic advances. While AAV-mediated gene transfer has proven effective in 
animal models for other urea cycle disorders including deficiencies of ornithine transcarbamylase6, 
argininosuccinate synthetase7, argininosuccinate lyase8, and arginase 19, no gene therapy strategies 
using AAV have yet been established for CPS1 deficiency for multiple reasons. First, until recently 
there were no viable animal models of CPS1 deficiency. While a neonatal murine model was 
developed 20 years ago10, this was not submitted to a repository and was lost for future 
investigation11. In that model, neonatal mice perished within the first 24 hours after birth; 
developing therapies in a newborn mouse with the early intake of milk and consequent early rise 
in plasma ammonia poses significant challenges. As an alternative to that neonatal model, an adult 
model of CPS1 deficiency was recently established utilizing primary human hepatocytes from 
patients transplanted into immune compromised mice and expanded in vivo12. However, this model 
suffers from being technically challenging and time consuming, in addition to requiring access to 
a relatively rare cell population. Second, CPS1, being the most abundant mitochondrial protein in 
human liver, must be expressed at high levels in hepatocytes. The enzyme itself accounts for 15-
20% of the total mitochondrial protein as a 165,000 molecular weight polypeptide 1; its expression 
is pan-hepatic13, 14, not exclusively periportal like some of the other urea cycle enzymes, further 
leading to challenges of obtaining adequate expression. This is in contrast to gene therapy targets 
such as hemophilia that require as little as 1-2% protein levels to achieve therapeutic benefit15. 
Finally, the size of the CPS1 cDNA at 4.5kb, and limitations of the transgene expression cassette 
to ~5kb to maximize packaging efficiency, may be the greatest hindrance for a clinically 
translatable vector that can be produced at high titer such as AAV; with inverted terminal repeats 
and regulatory elements, the genome size easily exceeds the canonical limit of AAV. 
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Vector systems exist to package and deliver large transgenes, though they have significant 
drawbacks. Adenoviral vectors are highly immunogenic16, while lentiviral vectors suffer from low 
titer and random, widespread genomic integration17. Plasmids can be difficult to deliver and are 
largely silenced due to the presence of bacterial genomic elements18. To overcome these 
limitations, an approach was developed to capitalize on the recombinogenic nature of AAV 
vectors. This is achieved by generating two separate AAVs that contain complementary halves of 
a transgene cassette that includes a region of homology between them. These so-called dual or 
split AAVs (sAAVs) can potentiate homologous recombination between the vectors upon co-
transduction of the same cell19, 20, resulting in expression of the full-length therapeutic transgene. 
Variations on this system include relying on ITR-mediated concatemerization and subsequent 
removal by splicing, known as trans-splicing19 and the hybrid approach, which combines elements 
from both the overlapping and trans-splicing approaches21. sAAV approaches have been 
implemented successfully in, amongst others, the retina for Alström syndrome22, skeletal muscle 
for dysferlin deficiency23, 24, and the liver for glycogen storage deficiency type III25. 
 Here we describe the design and implementation of a sAAV dual vector approach to treat 
CPS1 deficiency. Specifically, using our recently established conditional knockout murine model 
of CPS1 deficiency26, we demonstrate that sAAV-mediated gene transfer is able to restore CPS1 
hepatic expression, control plasma ammonia, and re-establish ureagenesis. These studies lay the 







In Vitro Transduction with sAAVs Leads to RNA and Protein Expression of hcoCPS1 
A schematic of the sAAV strategy is depicted in Figure 1A. Two separate viral vectors 
were prepared: the first (5’ [or left] sAAV) contains the constitutively active CMV 
enhancer/chicken β-actin promoter (CAG) and the 5’ half of the human codon-optimized CPS1 
transgene (hcoCPS1) (cDNA base pairs 1-2181); the second virus (3’ sAAV [or right]) contains 
the 3’ half of hcoCPS1 (cDNA base pairs 1714-4521) and the rabbit β-globin polyadenylation 
sequence. A 467bp region of homology within the transgene (overlap) potentiates homologous 
recombination upon co-transduction of the same cell, resulting in the reconstituted full-length 
transgene with no intervening viral ITR (combined sAAV).  
To determine if sAAVs containing hcoCPS1 have the same propensity for homology-
directed concatemerization as previously tested transgenes by others20, 27, HEK 293T cells were 
transduced with sAAVs followed by genomic DNA extraction. There was a dose-dependent 
increase (log increments from 102 to 105 viral genomes/cell) in detectable concatemerized product 
when amplified using primers to specifically recognize either the 5’ (primers LF and LR), 3’ 
(primers RF and RR), or combined sAAV (primers LF and RR) (Figure 1B; primers shown as 
black half-arrows in Figure 1A). To show that concatemerization leads to gene and protein 
expression, HeLa and 293T cells were transduced, and RNA and protein, respectively, extracted. 
Gene expression analysis by qPCR demonstrated that the individual halves of hcoCPS1 are only 
detectable in cells transduced with the relevant sAAV (relative to non-transduced cells) (Figure 
1C; primers shown as red/blue arrows in Figure 1A). CPS1 protein levels were also increased over 
endogenous levels in 293T cells transduced with both sAAVs (2.7-fold increase relative to non-




In Vivo sAAV Treatment Extends Lifespan of Cps1-Deficient Mice  
Following in vitro testing, sAAVs were tested for therapeutic efficacy in vivo. A diagram 
of the general workflow is depicted in Figure 2A. To determine the optimal viral dose for 
subsequent in vivo studies, adult female Cps1 conditional knockout mice (Cps1flox/flox) were 
injected with AAV8-Cre (as described previously26) and increasing doses of sAAVs ranging from 
1x1013 genome copies (GC)/kg to 3x1014 GC/kg of each virus (Figure 2B; n = 3 per dose). The 
minimum dose required to extend lifespan to 30 days in all mice in a group was 3x1014 GC/kg. 
Because the mice at the highest dose still showed a slight decline in body weight (data not shown), 
a surrogate for overall health, in addition to our previous work demonstrating that therapeutic 
CPS1 level requirements are relatively high26, all subsequent studies were carried out with 5x1014 
GC/kg/virus. No acute or chronic side effects were seen at this dose, and plasma alanine 
aminotransferase levels (ALT, collected on day 36) were not significantly different from control 
mice (sAAV-treated: 31.8 ± 3.0 U/L, n = 4; wild type: 37.8 ± 12.7 U/L, n = 5; p = 0.69) 
(Supplemental Figure 1A). 
To investigate the ability of sAAVs to treat CPS1 deficiency, adult Cps1flox/flox mice were 
injected with AAV8-Cre alone (referred to as untreated) or in combination with sAAVs at 5x1014 
GC/kg (referred to as treated; n = 5 each for both males and females, all groups). At this dose, 
both female and male mice survived beyond 120 days (Figure 2C), significantly longer (p < 
0.0001) than untreated controls that perished by day 22 (females: range 19-22 days) or 21 (males: 
range 17-21 days). 
The studies with the female mice began first. All untreated Cps1-/- mice (Figure 2D, black 
line) had significant weight loss and died or were euthanized due to humane endpoints by day 22. 
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By day 38, treated female Cps1-/- mice began to slowly lose weight (10% of their starting weights) 
(Figure 2D, red line). As an additional intervention in the treated Cps1-/- mice, N-carglumic acid 
(NCA), a structural analog of the Cps1 allosteric activator NAG (and the active ingredient in 
CarbaGlu©), was added to the drinking water to increase CPS1 activity (Figure 2D, red arrow F1); 
dextrose (5%) was also included in the water to encourage consumption. Dextrose/NCA-treated 
female mice subsequently regained the lost weight and continued to gain over time (red line). 
These mice were dependent on this supplementation as its withdrawal (red arrow F2) resulted in 
weight loss prior to re-administration (beginning at red arrow F3). In addition, NCA treatment 
alone, without dextrose, was sufficient to maintain stable weights (Figure 2D, red arrow F4) and 
plasma ammonia levels (Supplemental Figure 1B, p = 0.8). With these findings in the female mice, 
male mice (blue line) were subsequently administered water with dextrose/NCA beginning at day 
14 (blue arrow M1). 
 
sAAV Treatment Improves Biochemical Profiles of Cps1-Deficient Mice 
To understand the extent of the therapeutic response, plasma ammonia was measured in 
AAV8-Cre-only treated Cps1-/- (i.e. untreated), sAAV-treated Cps1-/- (i.e. treated), and wild type 
mice (n = 5 per group for both males and females). At day 21, plasma ammonia levels in treated 
mice (red line) were significantly lower than untreated control mice (black line) in both females 
(339.0 ± 42.3 µM vs. 1244.6 ± 180.9 µM [treated vs. untreated, respectively], p < 0.01) and males 
(581.3 ± 60.9 µM vs. 1090.4 ± 166.7 µM, p = 0.021) (Figure 2E and F). At 120 days, compared to 
baseline (Day 0) levels, females (138.9 ± 38.7 µM [Day 0] vs. 464.3 ± 65.0 µM [Day 120], p = 
0.026) and males (231.8 ± 41.9 µM [Day 0] vs. 601.0 ± 53.7 µM [Day 120], p = 0.033) 
demonstrated controlled plasma ammonia, albeit females with superior control.  
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To further investigate metabolic health, untreated Cps1-/-, sAAV-treated Cps1-/-, and wild 
type mice underwent urea cycle-related plasma amino acid profiling to determine the extent of 
residual metabolic derangement (Figure 3). In untreated female Cps1-/- mice (black line) compared 
to wild type controls (blue line), though not statistically significantly, arginine trended towards 
reduction (p = 0.067) (Figure 3A), while citrulline (p = 0.70) and ornithine were not significantly 
reduced (Figure 3B and C, black lines). In contrast, glutamine was significantly elevated in Cps1 
deficiency at the time of death relative to wild type controls (853.4 ± 74.9µM vs. 630.6 ± 18.9µM; 
p = 0.03) (Figure 3D). Alanine, a non-toxic molecular carrier of nitrogen, was reduced at baseline 
(269 ± 9.5µM vs. 356.2 ± 8.0µM, p < 0.01) but increased slightly by day 21 in Cps1-/- mice when 
they perished (p = 0.5), while glutamate did not significantly increase (Figure 3F). Conversely, 
sAAV-treated females (red line) showed no significant differences compared to wild type mice in 
plasma arginine, citrulline, glutamate, and glutamine (Figure 3A, B, D, and F [red lines], 
respectively). Ornithine was significantly reduced in treated mice at days 21 (38.1 ± 5.8µM; p = 
0.03) and 60 (36.5 ± 4.1µM; p = 0.02) compared to wild type controls (64.2 ± 3.9µM), though not 
at days 30 and 120 (p = 0.8 and 0.13, respectively) (Figure 3C). Alanine levels were not 
significantly elevated compared to wild type controls (Figure 3E). 
 Like the female mice, untreated Cps1-/- males (black line) showed a trend towards reduced 
arginine levels compared to wild types (50.6 ± 5.2µM vs. 64.6 ± 4.1µM; p = 0.066) (Figure 3G) 
while citrulline was also reduced, however not significantly different from wild type controls 
(Figure 3H). Ornithine was significantly reduced at time of death compared to wild type mice (30.6 
± 5.9µM vs. 45.2 ± 2µM, p = 0.047) (Figure 3I) while plasma glutamine was significantly elevated 
compared to wild type mice (932.9 ± 73.1µM vs. 487.3 ± 46µM; p < 0.001) (Figure 3J), as 
expected; however, alanine and glutamate showed no significant differences in untreated Cps1-/-
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mice compared to wild type controls (Figure 3K and L). In contrast, treated male mice (red line) 
had significantly elevated arginine at days 21, 30, and 60 (peak at day 30: 109.7 ± 12.9µM, p = 
0.01) compared to wild type mice (Figure 3G). Citrulline was also significantly elevated at days 
60 and 120 compared to wild type mice (peak at day 60: 104.9 ± 10µM vs. 67.2 ± 8.3µM, p = 
0.019) (Figure 3H) while ornithine was significantly reduced at days 21 and 60 (trough at day 60: 
33 ± 0.9µM, p < 0.001), though not at days 30 and 120 (Figure 3I). Similar to untreated controls, 
glutamine was significantly elevated in treated mice from day 21 to the end of the study at day 120 
(peak at day 60: 1090 ± 96.9µM, p < 0.001) compared to wild type control mice (Figure 3J), while 
alanine was significantly elevated at days 30 and 60 relative to wild type mice (peak at day 30: 
497.2 ± 59.8µM vs. 293.9 ± 21.3µM, p = 0.012) (Figure 3K). Glutamate showed no significant 
differences from wild type mice (Figure 3L). 
 
Acutely Elevated Ammonia Is Metabolized by Female but not Male sAAV-Treated Mice 
To measure the ability of sAAV-treated mice to metabolize ammonia into urea, sAAV-
treated and wild type mice (male and female, n = 5 per gender) were subjected to an acute ammonia 
challenge by injection with 4 mmol/kg of 15N-labeled ammonium chloride (Figure 4A). Plasma 
samples were taken before (time 0) and at 10, 20, 30, 60, and 90 minutes after injection to measure 
the plasma ammonia and ureagenesis capacity. In sAAV-treated females (red line), plasma 
ammonia peaked relative to baseline at 20 minutes (535.4 ± 40.4µM vs. 2471.0 ± 317.4µM; p < 
0.01) and subsequently decreased over time, with a trajectory toward baseline levels by 90 minutes 
after injection (937.0 ± 167.0µM; p = 0.16) (Figure 4A, red line). Wild type control female mice 
had a reduced peak ammonia and a more rapid correction to baseline ammonia levels (blue line). 
Mice were scored at 15 minutes post-injection to examine for any behavioral abnormalities. 
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Treated females averaged a score of 6 (range: 4-7; 7 being no signs of abnormal behavior, i.e., no 
noticeable differences from wild types) with no seizure activity while all wild type mice were 
scored at 7 (Supplemental Table 1). 
The results were strikingly different with the male mice. While all female mice completed 
the challenge, only 2 treated male mice (orange line) survived until the 90-minute time point; the 
others perished during the challenge (i.e. seizure activity and death). Ammonia levels in treated 
males, which were higher than females at time 0, reached greater levels above baseline at 20 
minutes (n = 4 mice; 3389 ± 348.2µM; p < 0.05) and continued to climb during the challenge 
without returning towards baseline levels (90 minutes: n = 2 mice; 5292.5 ± 841.5µM) (Figure 4A, 
orange line). Similar to the females, male mice were also scored for behavioral abnormalities at 
15 minutes post-injection: treated males scored substantially worse however, averaging only a 
score of 4 (range: 3-6; p = 0.067) (Supplemental Table 1); 2 male mice died shortly after with 
seizure activity. All wild type males scored either 6 or 7 (n = 3 scored 6, n = 2 scored 7). 
In female mice, concomitant with decreases in plasma ammonia, plasma [15N]-urea 
increased over time before reaching equilibrium at 30 minutes in wild type (blue line) and 60 
minutes in sAAV-treated mice (red line) (Figure 4B, p = 0.29 at 60 minutes). To compare the 
maximum ureagenic output, the instantaneous rate of ureagenesis was calculated from the slope of 
the best-fit curve of percent enrichment at time 0, which subsequently demonstrated that sAAV-
treated females have 60.3% of wild type capacity (0.53 ± 0.04% enrichment/min vs. 0.88 ± 0.04% 
enrichment/min [sAAV-treated vs. wild type, respectively], p < 0.001) (Figure 4C). Male sAAV-
treated mice (orange line) also showed gradual incorporation of 15NH4Cl into urea, though at a 
significantly reduced rate; [15N]-urea enrichment did not reach equilibrium in these mice (Figure 
4B, p < 0.01 at 60 minutes relative to wild type males [black line]). Males produced [15N]-urea at 
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a reduced instantaneous rate compared to wild types (0.27 ± 0.03% enrichment/min vs. 0.86 ± 
0.08% enrichment/min, respectively, p < 0.001), representing 31.4% wild type capacity (Figure 
4C). 
 
hcoCPS1 Transgene and Protein Expression is Upregulated in sAAV-Treated Mice 
To measure the amount of hcoCPS1 transgene expression, sAAV-treated mice (n = 5 per 
group per gender) were euthanized after 120 days post-injection of AAV8-Cre and sAAVs, and 
livers were removed for molecular analysis. Total DNA was extracted, and vector copy number 
was determined (Figure 5A). There was no significant difference seen in the amount of 5’ and 3’ 
sAAVs as copy number per diploid genome in females (5’ [left]: 90.08 ± 37.64, 3’ [right]: 78.46 
± 32.57; p = 0.82). However, in the male mice, there was near statistical significance in the 
difference in the amount of 5’ and 3’ sAAVs (left: 132.48 ± 28.67, right: 62.08 ± 10.76; p = 0.051). 
Total RNA was isolated and used to generate cDNA for qPCR analysis. Using primers that 
amplify hcoCPS1 and endogenous Cps1 mRNA (located on the left sAAV), both AAV8-Cre-only 
(untreated Cps1-/- [n = 5]: 0.02 ± 0.02 fold (2% of wild type), p < 0.0001; black bar) and sAAV-
treated Cps1-/- (treated [n = 5]: 0.24 ± 0.07 fold (24% of wild type), p < 0.001; red bar) females 
had reduced total CPS1 mRNA relative to wild type Cps1 gene expression (blue bar) (Figure 5B, 
left). In male mice, total CPS1 mRNA levels were significantly reduced compared to wild types 
in both untreated [n = 5; black bar at X-axis] and sAAV-treated [n = 5; red bar] mice (0.0009 ± 
0.0005 fold (<1% of wild type) and 0.03 ± 0.008 fold (3% of wild type), respectively; p < 0.0001 
for both groups) (Figure 5B). 
Liver tissue was used to assess protein levels. In females, sAAV-treated mice showed 
reduced but substantial CPS1 protein expression compared to the Cps1 protein of wild type 
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controls by Western blot (41.7% ± 11.5, p < 0.05 [n = 5]), and trending towards significantly more 
than untreated controls (17.3% ± 4.9, p = 0.08 [n = 5]) (Figure 5C, left); however, CPS1 protein 
in males was substantially less than wild type Cps1 protein (10.2% ± 3.5, p < 0.0001 [n = 5]) 
(Figure 5C, right), and lower than untreated controls (27.2% ± 2.3, p < 0.01 [n = 5]), likely only 
achieving sAAV-based expression just at the level to provide survival with persistent nitrogen 
vulnerability. Similar differences between untreated and treated mice are seen in tissue sections 
stained for CPS1 (red). Particularly in females, treated mice show CPS1 protein broadly distributed 
in the parenchyma with little or no residual endogenous expression visible in untreated mice 
(Untreated: 85.0 ± 27.3 CPS1+ cells/field; sAAV-treated: 446.5 ± 92.9 CPS1+ cells/field, p < 0.01) 
(Figure 5D, top images). Male sAAV-treated mice also had increased quantities of CPS1+ cells 
relative to untreated mice (sAAV-treated: 417.4 cells ± 80.1; untreated: 34.0 cells ± 20.8; p < 0.01) 
(Figure 5D, top images). An enzymatic functional assay was performed on liver lysates to examine 
the amount of CPS1 activity in sAAV-treated mice (n = 5 per gender per group). Female treated 
mice analyzed after day 120 showed enzyme function of 31.3 ± 6.6% relative to wild type controls 
(p < 0.0001) (Figure 5E, left). In males, treated mice had 15.0 ± 1.6% of wild type activity (Figure 
5E, right; p < 0.0001). Taken together, these results demonstrate that sAAV-derived hcoCPS1 
expression leads to substantial gene and protein expression in the livers of treated mice, albeit to 




CPS1 deficiency has two clinical presentations: i) neonatal onset, which is typically severe 
with high morbidity and mortality, and despite treatment, disease progression is difficult to 
prevent28; and ii) late onset, which has milder symptoms brought on by protein-rich meals, 
infection, pregnancy and the postpartum period, or other situations of high metabolic demand29. 
Biochemically, neonatal onset CPS1 deficiency results in markedly elevated plasma ammonia, 
leading to encephalopathy with growth and neurological deficits, along with an increase in plasma 
glutamine and a decrease of plasma citrulline and arginine5. In many cases, unrelenting 
hyperammonemia results in patient deaths. Orthotopic liver transplantation, while curative30, is 
limited due to an inadequate supply of available healthy donor livers and has risks of substantial 
complications31; no other curative treatment currently exists. CarbaGlu©, an FDA-approved 
treatment for N-acetylglutamate synthase (NAGS) deficiency, has been shown to be effective in 
treating a small subset of CPS1 patients32, though this is dependent on the nature of the mutation 
and is not broadly applicable to patients with complete protein loss. The development of novel and 
efficacious therapeutics is therefore essential to improve patients’ quality of life and prevent the 
morbidity and mortality that accompany this disorder. 
To have clinical benefit for patients afflicted with CPS1 deficiency, an effective therapy 
would need to maintain plasma ammonia in an acceptable range and resolve or prevent 
hyperammonemic episodes to avoid repeated neurological injury. However, the development of a 
gene therapy approach for CPS1 deficiency is challenged not only in part by 1) the large size of 
the cDNA, and 2), until recently, the lack of a clinically relevant animal model of the disorder, but 
also the expectation of a need for high-level mitochondrial protein expression based on its 
abundant quantity in normal hepatocytes 1. A recent manuscript employed mathematical modeling 
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to study ureagenesis of the individual urea cycle enzymes33, confirming this expectation. A 
progressive decline in ureagenesis was predicted using a one compartment model when liver-wide 
CPS1 activity was reduced below 50%. In contrast, ureagenesis was not predicted to decline until 
enzyme activity was below 3% for ornithine transcarbamylase, 20% for argininosuccinate 
synthetase, 3% argininosuccinate lyase, and 0.5% for arginase activity. 
While our group redeveloped a constitutive Cps1 knockout murine model34, we chose to 
test the AAV vector approach in our recently developed conditional Cps1 knockout mouse 26, 
avoiding investigating this treatment in mice that perish within the first 24 hours after delivery, are 
very small (~1 gram in size), and develop hyperammonemia shortly after birth with early intake 
of milk 34. Use of the conditional model allowed for proof-of-concept studies avoiding these further 
model complexities. Recent work from our laboratory developing and characterizing the 
conditional Cps1 knockout mouse model also had demonstrated both the model’s amenability to 
gene therapy strategies26 and as a representative model of CPS1 deficiency. The use of an AAV 
encoding Cre recombinase does introduce a small amount of mouse-to-mouse variability in this 
model; however, at the dose used here, no appreciable differences were seen in the efficiency of 
knock out. 
While AAV is an efficient gene therapy vehicle, its limited ability to package large DNA 
sequences with the cis regulatory elements necessary for expression is a significant limitation in 
its application to certain disorders. To address the large size of the CPS1 cDNA, we took an 
approach taking advantage of the ability of AAVs to undergo intermolecular concatemerization by 
developing dual vectors with a region of homology, splitting the large transgene into two separate 
AAV vectors. However, there is inherent inefficiency of transgene expression by this approach; 
hepatocytes must be transduced by both vectors, intracellular head-to-head and tail-to-tail 
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concatemerization can occur, limiting successful reconstitution, and homologous recombination is 
required. Together these issues would typically be expected to result in expression that is lower 
than that achieved by single AAV vectors22, 35, 36. While it would likely be more efficacious if a 
single hcoCPS1 cDNA vector could be made, previous unpublished attempts by our lab to generate 
single AAV vectors expressing CPS1 were unsuccessful, despite repeated efforts. This is possibly 
due to excessive shearing and genome truncation caused by the oversized AAV genome; 
encapsidated oversized DNA tends not to be a pure population of large genomes but rather a 
heterogeneous mixture of mostly genomes truncated to 5 kb or less in size37-39. 
To address the need for high level expression, utilization of the dual vector approach 
allowed for incorporation of a large and strong promoter (the CMV enhancer/chicken β-actin 
promoter); together with codon optimization of the human CPS1 cDNA, therapeutically relevant 
expression levels of successfully recombined genomes to control plasma ammonia were achieved. 
The successful employment of these approaches has allowed us to overcome these major hurdles 
and permitted the AAV-based delivery and expression of CPS1, avoiding use of less ideal viral 
vectors that may have limited clinical translatability26. Despite previous reports of limitations in 
CAG-based vectors, such as transgene silencing, immune response to therapeutic protein, and 
tumorigenesis, no evidence for these effects were seen, similar to previously published work by 
others40. 
The studies described herein demonstrate the following results for a dual AAV gene 
therapy approach for CPS1 deficiency: 1) high doses of sAAV vectors with a strong constitutive 
promoter can lead to expression of CPS1 and result in long-term survival in both male and female 
mice; however there is a dependence on N-carglumic acid to allosterically activate the enzyme to 
increase the level of enzyme activity; 2) chronic control of plasma ammonia and glutamine (along 
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with alanine, another intermolecular carrier of nitrogen) is achievable, albeit better in females; and 
3) acute control of elevated ammonia and restoration of high-level ureagenesis is achievable in 
female mice. Untreated control mice perished early and exhibited many of the circulating amino 
acid perturbations typical of CPS1 deficiency5, which were notably reversed or mitigated by sAAV 
treatment. 
However, this approach was met with an unexpected result. While female Cps1-/- mice had 
near-equal transduction of both the 5’and 3’ sAAV vectors and long-term ammonia control with 
avoidance of marked hyperglutaminemia, similar control was not present in the male mice. In 
contrast to females, male sAAV-treated mice showed a marked increase in glutamine which 
remained elevated for most of the duration of the study. Elevated glutamine is a typical 
presentation in proximal urea cycle disorders, and this result supports the moderately elevated 
plasma ammonia levels and reduced ureagenesis capacity found in the male mice. N-carglumic 
acid (NCA) with dextrose supplementation was efficacious in contributing to improved nitrogen 
metabolism; as the active ingredient in CarbaGlu©, treatment was found to be effective to further 
assist in control of plasma ammonia long-term. However, NCA and dextrose alone were not 
sufficient to extend lifespan in mice that did not receive sAAV treatment (data not shown).  
Vector dosing in this study was based on weight and, not unexpectedly, male mice were 
larger. While the circulating blood volume of male compared to female mice is larger 41, this is not 
as great as the weight difference between genders; thus effectively an overall greater number of 
AAV genomes was administered to male mice. This is reflected in the viral DNA copy number 
per diploid genome of the 5’ sAAV: murine hepatocytes from male mice demonstrated nearly 50% 
more genomes (90.08 vs. 132.48 vector genomes per diploid nucleus, female vs. male, 
respectively) than hepatocytes from female mice. However, unexpectedly, the number of 3’ AAV 
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genomes in male hepatocytes was ~50% of the 5’ AAV and was only ~80% of the female 3’ AAV 
genomes per diploid nucleus. This reduced 3’ sAAV genome number in hepatocytes from male 
mice resulted in less full-length hcoCPS1 cDNA, CPS1 protein and enzymatic activity, and a 
reduced ability to handle an exogenous ammonia challenge with a reduction in ureagenesis. The 
mechanism responsible for this finding is unclear. As both genders received the same dose per 
kilogram of sAAVs, and male cells have been demonstrated to be transduced more efficiently42, 
male mice were expected to have more robust CPS1 enzymatic activity and to perform better than 
females in the exogenous ammonia challenge and ureagenesis experiments. Stochastic differences 
in vector copy number and sAAV concatemerization, sexually dimorphic AAV expression, and 
viral retention43 may have contributed to the differences seen between male and female mice in 
terms of mRNA and protein expression, enzyme activity, and tolerance to exogenous ammonia 
loading. Although previous studies have demonstrated that a doubling of vector dose does not 
reduce viral transduction35, it is possible that saturation from the larger number of virions (i.e. 
greater weight in males and thus a greater number of total virions administered) may occur at 
differential viral loads for females and males. In addition, to our knowledge only two studies using 
sAAVs have been conducted in both male and female animals44, 45, raising the possibility of 
sexually dimorphic responses to sAAV administration, concatemerization, expression, or retention 
that warrant further investigation. 
In this study, we injected mice with 5x1014 GC/kg/virus, which is higher than other reports 
for gene therapies. A recent study in nonhuman primates demonstrated vector-related toxicity at a 
dose of 2x1014 GC/kg 46, indicating that the high viral load could be a barrier to translation. Despite 
this, high vector dosing has been used for a clinical trial for Duchenne Muscular Dystrophy (2x1014 
vg/kg) (NCT03375164) and X-linked Myotubular Myopathy (3x1014 vg/kg) (NCT03199469). 
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Though no negative effects have been detected at this dose in our studies, such high vector dosing 
may pose a barrier in terms of production and cost. However, despite this dose, there was no 
evidence of acute toxicity or chronic liver injury in mice used in this study. In addition, we found 
that in a small cohort of females, a reduced dose of 2x1014 GC/kg/virus was still effective for long-
term survival (data not shown). Further vector optimization is required and may be achieved by 
transitioning to a trans-splicing19 or hybrid21 approach in contrast to the overlapping one used here, 
which we pursued first due to encouraging early results. Both alternative strategies warrant further 
investigation for their potential capacity to reduce the viral load necessary for therapeutic benefit. 
In summary, we have shown for the first time that CPS1 deficiency may be treated using a 
split AAV-based gene therapy approach. This work bridges the gap between previously described 
pre-clinical efforts and more translatable tools to deliver therapeutic CPS1 protein safely and 
effectively. To date, no other potentially clinically translatable nucleic acid or protein replacement 
strategies have been successfully implemented to treat CPS1 deficiency.  
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Materials and Methods 
Animal Care and Mouse Procedures 
All mice were kept according to the National Institutes of Health guidelines and all 
experimental procedures were approved by and conducted according to the guidelines of the 
Institutional Animal Care and Use Committee. Unless otherwise stated, mice had ad lib access to 
standard chow and water and were maintained on a 12-hour light-dark cycle. Cps1flox/flox mice on 
the C57BL/6 background had been developed as previously described 26 and were used for all of 
the studies. Genomic DNA was prepared from ear clip by standard methods and genotyping was 
performed by PCR amplification as previously described26. 
Mice were randomly assigned to either the control or the experimental group. Male and 
female mice were equally represented throughout the study. For injections, AAV was diluted in 
sterile pharmaceutical grade 0.9% saline (Medline, Northfield, IL, 5T-NFSF-10011) and injected 
intravenously by a retro-orbital approach under isoflurane anesthesia. AAV8 TBG-Cre 
recombinase (University of Pennsylvania Vector Core, Philadelphia, PA) was administered 
(2x1011 GC/mouse, a dose previously demonstrated to result in Cps1 deficiency in this model26) 
simultaneously with the sAAVs. All mice were weighed daily and closely monitored for any signs 
of deteriorating health. Ill-appearing mice (e.g. disheveled fur, hunched appearance, lethargy) were 
euthanized at a humane endpoint prior to expiration. Mice receiving N-carglumic acid (NCA)-
supplemented water were administered a dose of 200mg/L NCA (Sigma-Aldrich, St. Louis, MO, 
C4375-10G) with 5% (w/v) dextrose (Sigma-Aldrich, G8270); water was replaced daily for 
females and every 2-3 days for males (on an as-needed basis). Scheduled blood sampling was 
obtained from the retro-orbital plexus under isoflurane anesthesia with plasma frozen immediately 
and stored at -80°C until analysis. Samples of liver were either snap frozen at the time of euthanasia 
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Full-length codon-optimized human CPS1 (hcoCPS1) was synthesized by Blue Heron 
Biotech (Bothell, WA). A 467-bp region encompassing base pairs 1714-2181 of the hcoCPS1 
transgene was used as the region of homology between the left and right sAAVs. The size of the 
overlapping region was chosen based on previous data demonstrating that increasing overlap 
length does not significantly improve recombination efficiency47. Molecular cloning of viral 
vectors was performed according to standard practices. 5’ sAAV: The viral backbone (p1044, 
provided by the University of Pennsylvania Vector Core) containing AAV2 ITRs was digested 
with KpnI and XhoI (all restrictions enzymes purchased from New England Biolabs [Ipswich, 
MA]); the CAG promoter was digested with KpnI and SalI; hcoCPS1 was then PCR-amplified 
(cDNA base pairs 1-2181) and subsequently digested with KpnI and SalI. Inserts were ligated with 
Quick Ligase (New England Biolabs, M2200S) into the backbone at a 3:1 molar ratio and 
transformed into Stbl3 E. coli (Invitrogen, Carlsbad, CA, C737303). 3’ sAAV: The same viral 
backbone as the 5’ sAAV was digested with BamHI; hcoCPS1 was PCR-amplified (cDNA base 
pairs 1714-4521) and subsequently digested with BglII. hcoCPS1 was ligated and transformed 
similar to the 5’ sAAV. The sequences for all primers used here are listed in Supplemental Table 
2. PCR conditions for amplifications using Platinum SuperFi DNA polymerase (Thermo Fisher 
Scientific, Boston, MA, 12351010) were: 95°C for 30s; 67°C for 30s; 72°C for 90s; repeat for 35 
cycles. Both constructs were verified by restriction digest and subsequently with sequencing. Viral 
amplification and purification of serotype 8 vectors were completed at the University of 
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In Vitro Transduction 
 HEK 293T and HeLa cells were grown in Dulbecco’s modified eagle medium (11885-084) 
supplemented with 10% fetal bovine serum (10437028), 1% GlutaMAX (35050061; all from 
Invitrogen), and 0.1mg/mL primocin (Invivogen, San Diego, CA, ant-pm-1). Prior to transduction, 
all cells were passaged and plated at a density of 5.3x104 cells/cm2. The following day, cells were 
transduced with increasing sAAV serotype 8 viral genomes/cell in log increments from 102 to 105 
(DNA from 293T cells) or 106 (RNA and protein from HeLa and 293T cells, respectively) in 
growth media supplemented with 5µg/mL polybrene (Vector Builder, Chicago, Il) and incubated 
overnight (approximately 16 hours). Virus was removed from cells in the morning following 
transduction by changing to fresh growth media, and cells were grown one additional day in growth 
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media. Cells were then harvested, and total DNA extracted (Qiagen, Germantown, MD, 69504). 
PCR amplification was performed with Taq DNA Polymerase (Qiagen, 201443). PCR conditions: 
95°C for 30s; 60°C for 30s, 72°C for 60s for 35 cycles. RNA was extracted, cDNA synthesized, 
and qPCR performed for hcoCPS1 as described below. Protein was extracted and analyzed by 
western blot as described below. 
 
Immunohistochemistry 
Whole livers were collected and analyzed as described previously 26. Briefly, tissues were 
prepared using standard procedures by fixing in 10% buffered formalin and storing in 70% ethanol 
until embedding in paraffin. Blocks were sectioned at 4µm thickness onto glass slides. Sections 
were baked at 60°C for 1 hour before being deparaffinized in xylene and rehydrated in serial 
ethanol washes. Slides were boiled in 10mM sodium citrate pH 6.0 to retrieve antigens before 
permeabilization in 0.1% Triton X-100. Sections were blocked with 10% Normal Goat Serum and 
incubated with primary antibodies overnight at 4°C. After washing, secondary antibodies were 
incubated for 1 hour at RT, followed by washing and mounting with VectaShield containing DAPI 
(Vector Laboratories, Burlingame, CA, H-1200). Primary antibodies used were: CPS1 (Abcam, 
Cambridge, MA, ab45956, used at 1:1000); GS (Abcam, ab64613, used at 1:1000). Secondary 
antibodies used were: goat anti-mouse FITC (against GS primary antibody; Invitrogen, M30101, 
used at 1:200); goat anti-rabbit AF594 (against CPS1 primary antibody; Invitrogen, A-11012, used 







qPCR was performed as described26. Briefly, total RNA was extracted and used to generate 
cDNA for the PCR reaction according to the manufacturer’s instructions (Roche, Indianapolis, IN, 
11828665001 and 4897030001, respectively). qPCR was carried out using BioRad ssoAdvanced 




Unfixed frozen liver was homogenized, and soluble protein was isolated in RIPA buffer 
(ThermoFisher Scientific, 89900) and HALT protease inhibitor (ThermoFisher Scientific, 78430). 
Protein was quantified using BioRad protein assay dye (BioRad, 5000006). Protein was loaded 
into a 12% gel (BioRad, 4561045) and transferred to PVDF membranes using the TransBlot Turbo 
system according to the manufacturer’s instructions (BioRad, 1704156). Membranes were blocked 
in 5% milk and incubated with primary antibodies overnight at 4°C. Secondary antibodies were 
incubated for 1 hour at RT before detection with SuperSignal West Pico PLUS (ThermoFisher 
Scientific, PI34579). Primary antibodies: anti-CPS1 (Abcam, ab45956, used at 1:1000); anti-β-
actin (Santa Cruz Biotechnology, Santa Cruz, CA, SC47778, used at 1:1000). Secondary antibody: 
goat anti-rabbit-HRP (against CPS1 primary; Santa Cruz Biotechnology, SC2004, used at 1:5000). 
No secondary antibody was used for β-actin as the primary antibody is HRP-conjugated. Semi-
quantitation was completed using NIH ImageJ version 1.51, normalizing to its own β-actin band 





Whole blood was collected by retro-orbital bleeding under isoflurane anesthesia into 
capillary tubes coated with sodium heparin (Spectrum Chemical, New Brunswick, USA, 631-
11095) and immediately centrifuged at 2000g for 10 minutes at 4°C. Plasma was collected and 
stored at -80°C until analysis. Ammonia levels were detected using a colorimetric ammonia assay 
(Abcam, ab83360) according to the manufacturer’s instructions. 
 
Ammonia Challenge & Ureagenesis 
Mice were fasted for 3-4 hours at the same time of the day. To simulate a nitrogen 
challenge, mice were injected by intraperitoneal method with a 4 mmol/kg solution of 15NH4Cl 
(Cambridge Isotope Laboratories, Andover, MA, NLM-467-1). At 15 minutes after injection, the 
mice were evaluated behaviorally by scoring from one observer using the scale outlined in 48. 
Blood was collected at the indicated time points after injection. Plasma was isolated and stored at 
-80°C until analyzed as described above for the ammonia assay. At each bleed, 5 μL of blood was 
dispensed in duplicate onto a filter paper card (Perkin Elmer, Waltham, MA, GR2261005) for the 
ureagenesis assay. 15N-labeled urea enrichment was determined on these samples by gas 
chromatography-mass spectrometry as previously described 49. 
 
CPS1 Enzyme Function Assay 
The activity of CPS1 was determined colorimetrically as previously described50 by 
assaying at 37°C in an ornithine transcarbamylase coupled reaction, where carbamoyl phosphate 
was immediately converted to citrulline. 
 
Amino Acid Analysis 
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The concentration of amino acids in plasma and liver was determined by high-performance 
liquid chromatography as previously described26. 
 
Statistical Analysis 
Collected data was analyzed with the Prism8 (GraphPad Software, San Diego, CA) 
statistical package. Results were expressed as mean ± standard error of the mean (SEM) and p 
values were determined using one-way ANOVA with Tukey’s multiple comparison’s test, or 
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Figure 1. In Vitro Characterization of sAAVs. A) Schematic of overlapping sAAVs. A 467bp 
overlapping region of homology (overlap) mediates homologous recombination between the 5’ 
(left) and 3’ (right) sAAVs, resulting in the full-length combined sAAV containing hcoCPS1 
(green-blue rectangles) and removing the intervening viral ITR. B) DNA: PCR amplification of 
left (top) and right (middle) sAAVs and the combined sAAV (bottom) with increasing viral 
genomes/cell in transduced HEK 293T cells. Amplicons are generated by primers indicated by 
black half-arrows in A (LF+LR amplify left sAAV; RF+RR amplify right sAAV); combined 
sAAV product is generated by amplifying with the outer primer of each pair, i.e., primers LF+RR. 
C) RNA: hcoCPS1 mRNA is detectable by qPCR in transduced HeLa cells. Primers used to 
amplify either half are indicated by red arrows (left sAAV) and blue arrows (right sAAV), and 
expression was normalized to GAPDH. Data presented are mean ± SEM of triplicate experiments. 
D) Protein: Western blot for CPS1 in HEK 293T cells either non-transduced ( - ; left lane) or 
transduced with both sAAVs ( + ; right lane); β-actin, loading control. (Note: increased density of 
CPS1 band from sAAV transduced cells.) Abbreviations: CAG, CMV enhancer/chicken β-actin 
promoter; sAAV, split adeno-associated viral vector; hcoCPS1, human codon-optimized 
carbamoyl phosphate synthetase 1; HEK, human embryonic kidney; ITR, inverted terminal repeat. 
*p < 0.05, **p < 0.01, ****p < 0.0001. 
 
Figure 2. sAAVs Promote Lifespan Extension and Weight Maintenance in Mice In Vivo. A) 
Workflow of in vivo sAAV administration. Adult Cps1flox/flox mice were injected with AAV8-Cre 
alone (mice depicted in brown) or in combination with sAAVs (mice depicted in gray) at time 0 
(top left). AAV8-Cre results in hepatic disruption of Cps1 expression resulting in loss of functional 
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protein. All mice were weighed daily to assess general health (bottom left), after which only the 
surviving sAAV-treated mice (gray) were subjected to an exogenous ammonia challenge after day 
120 (bottom right). Mice were subsequently euthanized, and the livers removed for molecular and 
biochemical analysis (top right).   B) Dose escalation of sAAVs in female AAV8-Cre-treated 
Cps1flox/flox mice. The minimum dose required to ensure survival to 30 days was determined to be 
3x1014 GC/kg/virus; n = 3 mice per group. C) Survival of 5x1014 GC/kg sAAV-treated (treated 
[red and blue lines]) mice and AAV8-Cre-only Cps1flox/flox (untreated [black and orange]) controls. 
D) Weight maintenance in sAAV-treated mice. AAV8-Cre-only mice (black, orange) rapidly lost 
weight beginning around day 14 after AAV8-Cre administration, while sAAV-treated mice (red, 
blue) did not. Red F-series arrows correspond to the red line of treated females; blue M-series 
arrow corresponds to the blue line of treated males. Red arrows F1 and F3 indicate administration 
of NCA and dextrose in female sAAV-treated mice (red line); red arrow F2 indicates removal of 
NCA and dextrose from sAAV-treated females; red arrow F4 indicates removal of dextrose only 
from NCA water for sAAV-treated female mice; note stability of weight without dextrose. Blue 
arrow M1 represents addition of NCA and dextrose to male mice. Plasma ammonia levels were 
measured in female (E) and male (F) mice. Legend is shared between E and F; day 21 data points 
for untreated mice represent values obtained at time of death or euthanasia and are grouped 
together for clarity. Data represent mean ± SEM with n = 5 mice per group; * p < 0.05; **p < 0.01. 
Abbreviations: NCA, N-carglumic acid; sAAV, split AAV; SEM, standard error of the mean. 
 
Figure 3. sAAV Treatment Improves Some Amino Acid Imbalances in Mice with Cps1 
Deficiency. Plasma amino acids show improvement in females (A-F) and moderate correction in 
males (G-L); note sustained elevation of glutamine in sAAV-treated male mice. Data represent 
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mean ± SEM, n = 5 per group except in treated females at day 0, where n = 4. Asterisks denote 
significant deviation from wild type values, where solid and dashed lines are mean and ± SEM, 
respectively; *p < 0.05, **p < 0.01, ***p < 0.001. 
Figure 4. Ammonia metabolism after exogenous ammonia loading. A) After a marked increase 
with exogenous administration of 15NH4Cl, plasma ammonia levels decrease towards baseline over 
90 minutes in female sAAV-treated mice (red line), albeit less rapidly than in wild type mice (blue 
line). In male sAAV-treated mice plasma ammonia levels do not decline (orange line). Asterisks 
denote significant deviation from baseline values within a gender. (Treated male mice data at 60 
and 90 minutes was n = 2 per time point due to animal deaths, along with large value variation 
accounts for statistical non-significance.) B) 15N-labeled urea is produced in mice treated with 
15NH4Cl, with enrichment peaking faster in wild type mice (blue, black) than in sAAV-treated 
mice (red, orange) of both genders. Legend is also shared with A. (A and B: For females at all time 
points and experimental groups: n = 5 per group. For males: n = 5 at time 0, n = 4 at time 20, and 
n = 2 at times 60 and 90 in the treated group due to animal deaths from seizure activity; n = 5 at 
all times for the wild type males.) C) Instantaneous rate of ureagenesis in female (n = 5, both 
groups) and male mice (n = 4 sAAV-treated and n = 5 wild type), based on best-fit curves from B. 
Data represent mean values ± SEM. Asterisks denote significant deviation from baseline values in 
the ammonia curves and wild type values in the urea curves; *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Figure 5. Molecular analysis of livers from treated mice. A) Vector copy number of both the left 
(5’) and right (3’) sAAVs in males (n = 5) and females (n = 5). B) Total CPS1 mRNA were 
measured by qPCR in AAV8-Cre-only (untreated), sAAV-treated (treated), and wild type mice for 
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both females and males (n = 5 per group per gender). C) Western blot for CPS1 protein. D) 
Immunofluorescent staining of liver tissue sections for CPS1 (red) and glutamine synthetase (GS) 
(green); nuclear stained with DAPI (blue). E) CPS1 enzyme functional assay on liver tissue lysates 
in both females and males (n = 5 per group per gender). Western blot and immunofluorescence 
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